Trial Profile
A phase III prospective randomized comparison of imatinib at a dose of 400mg in combination with peg-interferon-alpha2a (Peg-IFNa2a) or cytarabine (Ara-C) versus imatinib at a dose of 600mg versus imatinib a dose of 400mg for previously untreated chronic myelogenous leukemia (CML) in chronic phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Imatinib (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms French SPIRIT; SPIRIT
- 01 Aug 2021 Primary endpoint (Overall survival improvement) has not been met, according to the results published in the Leukemia.
- 01 Aug 2021 Results assessing the long-term outcomes of patients enrolled in the trial. Strategies concerning switches to a second-generation TKI (2GTKI) and discontinuation of treatment in DMR are reported, published in the Leukemia.
- 10 Oct 2016 Status changed from active, no longer recruiting to completed.